US Pre-emption ruling could damage innovation says HIMA
This article was originally published in Clinica
In a decision that could adversely affect every US medical device manufacturer, all nine judges of the US Supreme Court on June 26th agreed that the FDA's imprimatur does not protect companies from product liability suits in state courts. In their review of the legal arguments in the Medtronic vs Lohr case, in which the plaintiff is seeking damages for an allegedly faulty pacemaker lead, the judges ruled against Medtronic's pre-emption claims of 510(k) products covered under FDA regulation (see Clinica No 703, p 7).
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.